These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12798630)

  • 1. Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end.
    Lansley M; Bedford H
    Vaccine; 2003 Jun; 21(21-22):2877-81. PubMed ID: 12798630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; De Serres G; Niyonsenga T
    JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the federal state of Santa Catarina, Brazil.
    Kupek E; Puricelli RC; Westrupp MH
    Braz J Infect Dis; 2001 Dec; 5(6):324-31. PubMed ID: 11980595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross sectional survey of meningococcal C immunisation in children looked after by local authorities and those living at home.
    Hill CM; Mather M; Goddard J
    BMJ; 2003 Feb; 326(7385):364-5. PubMed ID: 12586668
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of meningococcal C conjugate vaccine use in Australia.
    Booy R; Jelfs J; El Bashir H; Nissen MD
    Med J Aust; 2007 Feb; 186(3):108-9. PubMed ID: 17309394
    [No Abstract]   [Full Text] [Related]  

  • 7. Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
    Gonçalves P; Sáez-López E; Carneiro S; Simões MJ
    PLoS One; 2021; 16(4):e0250103. PubMed ID: 33857245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
    Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
    Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enter B and W: two new meningococcal vaccine programmes launched.
    Ladhani SN; Ramsay M; Borrow R; Riordan A; Watson JM; Pollard AJ
    Arch Dis Child; 2016 Jan; 101(1):91-5. PubMed ID: 26672098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunisation update: Meningococcal B and ACWY vaccines.
    Davidson GT; Heaton PA; Paul SP
    J Fam Health; 2015; 25(6):22-5. PubMed ID: 26749934
    [No Abstract]   [Full Text] [Related]  

  • 14. Public policy for meningococcal vaccination.
    Cameron JC
    Hum Vaccin Immunother; 2018 May; 14(5):1216-1217. PubMed ID: 29194013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological pattern of meningococcal disease in Valencia, Spain. Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine.
    Pereiró I; Díez-Domingo J; Morant A; Gimeno C; Lerma M; San-Martín M; González A;
    Scand J Infect Dis; 2001; 33(8):581-4. PubMed ID: 11525350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France).
    Lévy-Bruhl D; Perrocheau A; Mora M; Taha MK; Dromell-Chabrier S; Beytout J; Quatresous I
    Euro Surveill; 2002 May; 7(5):74-6. PubMed ID: 12631934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
    Ramsay ME; Andrews NJ; Trotter CL; Kaczmarski EB; Miller E
    BMJ; 2003 Feb; 326(7385):365-6. PubMed ID: 12586669
    [No Abstract]   [Full Text] [Related]  

  • 18. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.